Certain inherited modes of heart failure and several neurodegenerative diseases are characterized by protein misfolding states whose underlying mechanism(s) and pathophysiology are poorly understood. Effective therapies exist primarily as goals, not as clinical implementations. Macromolecular damage induced by oxidative stress is the sine qua non for thinking about many diseases. Our laboratory has challenged this paradigm by demonstrating that mouse hearts exhibiting protein-folding cardiomyopathy found in humans are under 'reductive stress'from an over-active antioxidative system. Decreasing the function of glucose-6-phosphate dehydrogenase (G6PD), which generates the reductant NADPH, """"""""cures"""""""" the disease in mice by ameliorating reductive stress, aggresome formation, hypertrophy, heart failure and death. This experiment defines a novel causal mechanism and implicates G6PD as a potential therapeutic target. We hypothesize that stress response and anti-oxidative pathways undergo a pathogenic transition, and become dysregulated by macromolecular stresses (e.g., misfolded proteins). We further propose that other cardiac and neurodegenerative diseases result from similar pathogenic transition. Our Pioneer Award proposal is designed to develop a robust experimental platform for exploring the mechanisms of reductive stress disease. Our work will extend from studies that model reductive stress in the genetically amenable fruit fly Drosophila melanogaster, through cultured mouse and human cells, to whole mice, and finally into patients as we work to develop diagnostic tools. Cuttingedge imaging techniques will be developed for monitoring redox couples and toxicities in living cells and tissues. Genetic screens in Drosophila will guide the identification of new genes and determine the effects of potentially therapeutic compounds that prevent reductive stress disease. Validation in mice of interacting genes and pathways will provide us target candidates for pharmacolog

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
NIH Director’s Pioneer Award (NDPA) (DP1)
Project #
7DP1HL117650-05
Application #
8537969
Study Section
Special Emphasis Panel ()
Program Officer
Wong, Renee P
Project Start
2009-09-30
Project End
2014-07-31
Budget Start
2013-08-23
Budget End
2014-07-31
Support Year
5
Fiscal Year
2013
Total Cost
$720,997
Indirect Cost
$249,757
Name
Medical College of Wisconsin
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
937639060
City
Milwaukee
State
WI
Country
United States
Zip Code
53226
Su, Kuo-Hui; Cao, Junyue; Tang, Zijian et al. (2016) HSF1 critically attunes proteotoxic stress sensing by mTORC1 to combat stress and promote growth. Nat Cell Biol 18:527-39
Zhang, Huali; Limphong, Pattraranee; Pieper, Joel et al. (2012) Glutathione-dependent reductive stress triggers mitochondrial oxidation and cytotoxicity. FASEB J 26:1442-51
Benjamin, Ivor J (2012) Targeting endoglin, an auxiliary transforming growth factor ? coreceptor, to prevent fibrosis and heart failure. Circulation 125:2689-91
Christians, Elisabeth S; Benjamin, Ivor J (2012) Proteostasis and REDOX state in the heart. Am J Physiol Heart Circ Physiol 302:H24-37
Christians, Elisabeth S; Ishiwata, Takahiro; Benjamin, Ivor J (2012) Small heat shock proteins in redox metabolism: implications for cardiovascular diseases. Int J Biochem Cell Biol 44:1632-45